Related references
Note: Only part of the references are listed.Real-world effectiveness of cladribine for Australian patients with multiple sclerosis: An MSBase registry substudy
Nathaniel Lizak et al.
MULTIPLE SCLEROSIS JOURNAL (2021)
Autologous hematopoietic stem cell transplantation following alemtuzumab therapy in aggressive multiple sclerosis: A report of three cases
Giacomo Boffa et al.
MULTIPLE SCLEROSIS JOURNAL (2021)
Immune phenotyping study revealing caveats regarding a switch from fingolimod to cladribine
R. F. Radlberger et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2021)
Cladribine tablets versus other disease-modifying oral drugs in achieving no evidence of disease activity (NEDA) in multiple sclerosis-A systematic review and network meta-analysis
Halina Bartosik-Psujek et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2021)
Highly active RRMS and ocrelizumab after failure of alemtuzumab therapy
Martin Valis et al.
BMC NEUROLOGY (2020)
Consensus recommendations for the diagnosis and treatment of multiple sclerosis: 2019 revisions to the MENACTRIMS guidelines
B. Yamout et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2020)
Severe fingolimod rebound syndrome after switching to cladribine treatment
Fernanda Coss-Rovirosa et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2020)
Alemtuzumab: Rare serious adverse events of a high-efficacy drug
Hans-Peter Hartung et al.
MULTIPLE SCLEROSIS JOURNAL (2020)
Long-term management of multiple sclerosis patients treated with cladribine tablets: an expert opinion
Sven G. Meuth et al.
EXPERT OPINION ON PHARMACOTHERAPY (2020)
Cladribine vs other drugs in MS Merging randomized trial with real-life data
Alessio Signori et al.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2020)
Severe disease activity in MS patients treated with cladribine after fingolimod withdrawal
Maria Cellerino et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2020)
Infection risk with alemtuzumab decreases over time: pooled analysis of 6-year data from the CAMMS223, CARE-MS I, and CARE-MS II studies and the CAMMS03409 extension study
Sibyl Wray et al.
MULTIPLE SCLEROSIS JOURNAL (2019)
Effects of cladribine tablets on lymphocyte subsets in patients with multiple sclerosis: an extended analysis of surface markers
Olaf Stuve et al.
THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS (2019)
Activation of disease during therapy with alemtuzumab in 3 patients with multiple sclerosis
Thomas Wehrum et al.
NEUROLOGY (2018)
Management of MS-relapse during alemtuzumab therapy: Is it really B-cell-mediated?
Philipp Schwenkenbecher et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2018)
Systematic literature review and network meta-analysis of cladribine tablets versus alternative disease-modifying treatments for relapsing-remitting multiple sclerosis
Mohd Kashif Siddiqui et al.
CURRENT MEDICAL RESEARCH AND OPINION (2018)
Severe B-cell-mediated CNS disease secondary to alemtuzumab therapy
Aiden Haghikia et al.
LANCET NEUROLOGY (2017)
Cladribine to Treat Relapsing Forms of Multiple Sclerosis
Gavin Giovannoni
NEUROTHERAPEUTICS (2017)
Interpreting Lymphocyte Reconstitution Data From the Pivotal Phase 3 Trials of Alemtuzumab
David Baker et al.
JAMA NEUROLOGY (2017)
Both cladribine and alemtuzumab may effect MS via B-cell depletion
David Baker et al.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2017)
Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial
Jeffrey A. Cohen et al.
LANCET (2012)
Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial
Alasdair J. Coles et al.
LANCET (2012)
A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis
Gavin Giovannoni et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Share Paper
